Company intelligence
Partnology
Building Exciting Biotech Companies
About Partnology
Partnology is dedicated to the creation and nurturing of nascent biotech companies. Our strategy seamlessly links founders with aligned investors within the Venture Capital ecosystem. Not only do we actively participate in seed round investments, but when deemed beneficial, our executive search team recommends pivotal leadership figures, ensuring the dynamic progression of our partner companies.
Verified activity
Signals from Partnology
10 published signals
Capital & Finance
Partnology notes that AusperBio raised ~$120M in Series C financing to push its antisense therapy for chronic hepatitis B into Phase 3 and toward commercialization.
Reported by Partnology
Capital & Finance
Partnology notes that Genentech licensed next-generation antibody-drug conjugates from China-based DualityBio for $45M upfront and up to $1B+ in milestones.
Reported by Partnology
Capital & Finance
Partnology notes that Electra Therapeutics filed to go public, keeping 2026's IPO streak alive, with proceeds aimed at advancing its lead immunology antibody through Phase 2/3.
Reported by Partnology
Research & Knowledge
Partnology notes that Frontier Medicines is ramping up its ambitions after a tough stretch, advancing more cancer programs from its platform for undruggable targets.
Reported by Partnology
Research & Knowledge
Partnology notes that Cytokinetics is moving to expand Myqorzo into non-obstructive hypertrophic cardiomyopathy after positive late-stage data.
Reported by Partnology
Research & Knowledge
Partnology notes that Arrowhead Pharmaceuticals posted strong Phase 3 data on its triglyceride-lowering drug at ESC (~80% reductions and a 78% drop in acute pancreatitis events).
Reported by Partnology
Legal & Regulatory
Partnology notes that Revolution Medicines won approval for daraxonrasib in metastatic pancreatic cancer, the first drug to directly hit RAS, a target long considered undruggable and a major milestone in one of oncology's hardest indications.
Reported by Partnology
Legal & Regulatory
Partnology notes that Protagonist Therapeutics and partner Takeda won approval for rusfertide (Mimrylo), the first hepcidin-mimetic peptide cleared for polycythemia vera, giving the rare blood disorder its first therapy of this kind.
Reported by Partnology
Legal & Regulatory
Partnology notes that Genentech and BioNTech SE discontinued a personalized mRNA cancer vaccine after a Phase 2 showed worse survival than control.
Reported by Partnology
Capital & Finance
Partnology notes that Gilead Sciences secured approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults, extending its lenacapavir franchise.
Reported by Partnology